New strategies in chronic myeloid leukemia

Hagop M. Kantarjian, Jorge Cortes

Research output: Contribution to journalReview article

22 Scopus citations

Abstract

Most patients with chronic myeloid leukemia (CML) achieve clinically relevant hematologic and cytogenetic responses to imatinib. Patients who show resistance to imatinib need new therapeutic options. A range of options are being developed to treat imatinib-resistant patients who have CML. Promising results of early-phase clinical trials have been reported for new tyrosine kinase inhibitors, farnesyl transferase inhibitors, decitabine, homoharringtonine, and vaccines. Further clinical trials are needed to characterize the efficacy and safety profile of these new agents and to determine which agents improve the long-term prognosis for patients with CML who have shown resistance to imatinib.

Original languageEnglish (US)
Pages (from-to)289-293
Number of pages5
JournalInternational Journal of Hematology
Volume83
Issue number4
DOIs
StatePublished - May 1 2006
Externally publishedYes

    Fingerprint

Keywords

  • Bcr-Abl tyrosine kinase
  • Chronic myeloid leukemia
  • Protein
  • Tyrosine kinase

ASJC Scopus subject areas

  • Hematology

Cite this